CALCA and migraine disorder: This scenario is most relevant in the light of recent discussions about the sites of action of monoclonal antibodies, which are assumed to act outside the blood–brain barrier inhibiting CGRP signaling and reducing trigeminal functions involved in migraine (Russo 2015), as reviewed elsewhere (Edvinsson 2015) (DosSantos et al. 2014).